Long-term combination chemotherapy using eribulin and trastuzumab for three patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

The combination chemotherapy regimen of eribulin (ERI) and trastuzumab (TRA)—the ERI-TRA regimen—has been shown to be highly tolerable for patients with recurrent or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, no sufficient clinical evidence is availab...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Int Cancer Conf J
Hlavní autoři: Saeki, Toshiaki, Araki, Kazuhiro, Shimada, Ken, Shigekawa, Takashi, Nakayama, Hirofumi, Segawa, Yoshihiko, Mukai, Hirofumi
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Japan 2016
Témata:
Case Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6498262/
https://ncbi.nlm.nih.gov/pubmed/31149450
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13691-016-0253-y
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky